

NOV-03-2003 MON 03:37 PM ENANTA PHARMACEUTICALS

FAX NO. 6176070530

01

Docket Number: ENP-030

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

Applicant : Or et al.
Serial No. : 09/976,219
Filed : October 12, 2001
Title : Cyclosporin Analogs for the Treatment of Respiratory Diseases

Art Unit : 1653
Examiner : Samuel W. Liu

NOV 03 2003

TERMINAL DISCLAIMER TRANSMITTAL

Applicants are submitting herewith the following document:

- a) Terminal Disclaimer to Obviate a Provisional Double Patenting Rejection Over a Pending Second Application (09/975,923).

Please charge the requisite fees set forth under 37 CFR 1.20(d) for the submitted papers to Enanta Pharmaceuticals, Inc., Deposit Account No. 50-2010, referencing Attorney Docket No. ENP-030.

Respectfully submitted,

Date:

Nov. 3, 2003

Jason D. Ferrone
Reg. No. 52,887

Enanta Pharmaceuticals, Inc.
Attn: Patent Dept.
500 Arsenal Street
Watertown, MA 02472

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or being facsimile transmitted to the USPTO, on the date indicated below.

11/3/2003
Date of Deposit


Signature

Jason D. Ferrone
Typed or Printed Name of Person Signing Certificate

PTO/SB/25 (10-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING SECOND APPLICATION	Docket Number (Optional) ENP-030
<p>In re Application of: Or et al.</p> <p>Application No.: 09/976,219</p> <p>Filed: 10/12/2001</p> <p>For:</p> <p>The owner*, <u>Enanta Pharmaceuticals</u>, of <u>100.0</u> percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number <u>09/975,923</u>, filed on <u>10/12/2001</u>, of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.</p> <p>In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.</p> <p>Check either box 1 or 2 below, if appropriate.</p> <p>1. <input type="checkbox"/> For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <p>2. <input checked="" type="checkbox"/> The undersigned is an attorney or agent of record.</p> <div style="text-align: right;"> Signature</div> <div style="text-align: right;"><u>11/03/2003</u> Date</div> <div style="text-align: right;"><u>Jason D. Ferrone (Reg. No. 52, 887)</u> Typed or printed name</div> <p><input checked="" type="checkbox"/> Terminal disclaimer fee under 37 CFR 1.20(d) is included.</p> <p>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p> <p>*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/98 may be used for making this statement. See MPEP § 324.</p>	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.